1. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
- Author
-
Mustafa Altinbaş, Mustafa Gürbüz, Saadettin Kilickap, Necdet Uskent, Mert Karaoğlan, Nazim Serdar Turhal, Deniz Can Guven, Atakan Demir, Dogan Uncu, Teoman Sakalar, Cihan Erol, Suleyman Sahin, Semiha Urvay, Ahmet Z. Sahin, Sema Türker, Nuri Karadurmus, Abdullah Sakin, Atike Gökçen Demiray, Havva Yesil Cinkir, Mehmet Ali Nahit Sendur, Yakup Ergun, Filiz Çay Şenler, Erdem Cubukcu, Ramazan Acar, and Erman Akkus
- Subjects
0301 basic medicine ,Oncology ,Adult ,Bridged-Ring Compounds ,Male ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,medicine.medical_treatment ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Trastuzumab ,Stomach Neoplasms ,Internal medicine ,HER2 ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Chemotherapy ,Humans ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,Aged, 80 and over ,Taxane ,business.industry ,gastric cancer ,General Medicine ,Advanced gastric cancer ,Middle Aged ,Chemotherapy regimen ,First line treatment ,trastuzumab ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Taxoids ,business ,medicine.drug - Abstract
Purpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma. Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity. Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8–6.4) and 5.3 months (95% CI 2.6–8), respectively ( p = 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3–13.9) and 15.2 months (95% CI 12.7–17.7), respectively ( p = 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia. Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients.
- Published
- 2021